AstraZeneca, Daiichi Sankyo, and Summit Therapeutics to evaluate Datroway + ivonescimab combo across multiple tumour types October 6, 2026
United Immunity Announces Master Clinical Supply Agreement with Roche to Evaluate UI-102 + Anti–PD-L1 Therapy in Advanced Solid Tumors October 6, 2026
Abogen Announces Licensing and Option Agreement with Novartis to Advance mRNA-Encoded T-Cell Engager and other potential RNA programs October 6, 2026
FDA IND clearance for Ph 1 trial of CUR-001 in mesothelin-positive advanced refractory solid tumours October 6, 2026
Henlius and Amberstone Partner to Develop Next-Generation Conditionally Activated TCEs for Solid Tumours October 1, 2026
Perspective Therapeutics Announces Clinical Collaboration and Supply Agreement with Merck to Evaluate [212Pb]PSV359 in Combination with Keytruda in FAP-α Positive Solid Tumors September 16, 2026
First Patient dosed in Ph 1 Trial of CBX-663 for Treatment of Multiple Hematologic and Solid Malignancies September 16, 2026
US FDA IND Clearance and Australian Regulatory Clearance granted for [²²⁵Ac]Ac-FL-261 Ph 1 Clinical Trial September 16, 2026
FDA IND clearance to initiate a first-in-human Ph 1 trial of lead peptide-drug conjugate program TS-104 September 16, 2026
Styx Biotechnologies Announces Strategic Agreement with ZoeNCure Therapeutics to Accelerate Next-Gen ADC Pipeline to Clinic September 9, 2026
Treeline Announces Clinical Trial Collaboration and Supply Agreement with Roche to Evaluate TLN-121 with CD20xCD3 T-Cell-Engaging Bispecific Antibodies September 9, 2026
Evotec and Plectonic Enter Research Collaboration to Explore New Generation of T-Cell-Engaging Approaches for Solid Tumors September 9, 2026
China’s Simnova Bags USD59.5 Million in New Funding to Advance Off-the-Shelf Cell Therapies September 9, 2026
TScan Therapeutics Announces Strategic Reorganization to Focus on in vivo Cell Therapy for Solid Tumors September 9, 2026
Positive Outcome Announced from First Planned Interim Efficacy Analysis from FORTE Basket Study of Plixorafenib Monotherapy in Advanced Solid Tumors with BRAF Fusions September 9, 2026
